Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Several claims about Pepcid/famotidine and dosage forms are supported by the provided label excerpts (active ingredient; tablet strengths/forms; key indications include acid-related conditions). However, many claims about generic formulations (e.g., liquid) and marketing availability/strengths are not supported by the provided prescribing information. No direct label excerpts were provided for boxed warnings, and several general availability/history claims cannot be validated from the included sections.
Category Scores
Accurate Statements
Pepcid’s generic name is famotidine.
Label: Active ingredient is famotidine; and mechanism/clinical pharmacology sections describe famotidine as PEPCID's active component.
Famotidine is the active ingredient on generic Pepcid packaging.
Label excerpt provided: 'Active ingredient: famotidine' (and label context identifies famotidine as the drug substance for PEPCID).
Pepcid itself is a brand name and the generic equivalent is famotidine.
Label excerpt provided: 'Drug: PEPCID' / 'Active ingredient: famotidine'.
Generic famotidine is available as oral tablets in different mg strengths.
Label: '20 mg tablets' and '40 mg tablets' (Dosage forms and strengths) and Table 1 dosing for 20 mg/40 mg tablets.
Generic famotidine is used for acid-related conditions.
Label Indications: active DU, active GU, symptomatic nonerosive GERD, erosive esophagitis due to GERD; also hypersecretory conditions.
Generic famotidine is used for heartburn/acid indigestion as an H2 blocker.
Label Indications: symptomatic nonerosive GERD and erosive esophagitis due to GERD. Label Mechanism: 'competitive inhibitor of histamine-2 (H2) receptors' and inhibition of gastric secretion.
Unsupported Statements
A generic Pepcid is typically sold as famotidine tablets.
Provided prescribing information excerpt specifies PEPCID tablets and tablet strengths, but does not state market distribution of generic products as 'typically sold' as tablets.
A generic Pepcid is sometimes sold as liquid formulations depending on the product strength.
The provided excerpt mentions switching to other formulations 'e.g., oral suspension' for pediatric/renal adjustment, but does not support a general statement that generic Pepcid is sometimes sold as liquid formulations depending on strength.
Generic famotidine is commonly sold in multiple dose strengths and forms.
The excerpt confirms 20 mg and 40 mg tablets and mentions possible switching to other formulations in renal impairment, but does not support the broad claim that generic famotidine is 'commonly sold' across multiple forms.
Generic famotidine is available as an oral liquid.
The excerpt includes 'some dosage adjustments may require switching to other formulations of famotidine (e.g., oral suspension)' but does not explicitly state that generic famotidine is 'available as an oral liquid' for Pepcid generics.
Generic famotidine treats other stomach acid symptoms depending on the labeled indication and country’s product approvals.
The provided label excerpts list specific indications but do not support broad statements about additional 'other stomach acid symptoms' or 'country’s product approvals.'
Famotidine has been on the market for many years and is widely available as generics.
No provided prescribing information excerpt addresses market history or availability.
Contradictions
Important Omissions
Boxed warnings (if any) and a contraindication statement evaluation were not addressed in the AI claims list.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Most claims are informational and align with active ingredient and general acid-related indications. However, broad, unsupported statements about availability/formulations (e.g., liquid) and generalized use for 'other stomach acid symptoms' may lead to inaccurate assumptions about product forms/indications not evidenced by the provided label excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Several claims are general statements about market availability and formulation types that are not supported by the provided prescribing information excerpts.
Suggested Improvement
Limit claims to label-supported facts shown in the provided excerpts (famotidine as active ingredient; PEPCID tablet strengths/forms; label-indicated uses such as DU/GU/GERD; H2 receptor mechanism). Remove or qualify unsupported statements about generic packaging, oral liquid availability, 'commonly sold' forms/strengths, country-specific indications, and market history.